Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer
- 2 August 2019
- journal article
- research article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 36 (5) , 449-456
Abstract
Treatment with nivolumab improves survival and response rate in non-small cell lung cancer (NSCLC). Nevertheless, due to its high financial cost, identifying predictors of response to treatment has become an urgent need. Here, we focused on serum osteopontin (OPN), a pleiotropic protein overexpressed in lung cancer and involved in the immune response. A cohort of NSCLC patients (n = 72) treated with nivolumab was enrolled. Blood samples were collected at the time of first five nivolumab administrations. OPN and high-sensitivity C-reactive protein (hs-CRP) were assayed at each time point. The primary endpoint was to assess the predictive value of baseline serum levels of OPN towards overall survival (OS). Secondary endpoints included the potential association between OPN, hs-CRP and response to nivolumab. OPN and hs-CRP correlate with each other, with neutrophil count and biochemical markers of metastatic disease. At baseline, serum OPN increased with increasing Eastern Cooperative Oncology Group scale of Performance Status (ECOG PS). When Eastern Cooperative Oncology Group scale of Performance Status) (RECIST) criteria were considered, high baseline OPN levels were associated with a worse response to nivolumab. Cox hazard regression further confirmed baseline serum OPN as a predictor of mortality with the best predictive accuracy for serum levels above 37.7 ng/mL. Patients above the cut-off value had a higher mortality rate as compared to low serum OPN levels during follow up. Serum OPN may have a predictive role in NSCLC patients treated with nivolumab. Although larger confirmatory studies are needed, measuring serum OPN levels at baseline can be a clinically useful tool in a near future.Keywords
Funding Information
- Ministero della Salute
This publication has 33 references indexed in Scilit:
- Serum osteopontin levels are upregulated and predict disability after an ischaemic strokeEuropean Journal of Clinical Investigation, 2015
- Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.2014
- OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLCInternational Journal of Genomics, 2014
- Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasisJournal of Experimental & Clinical Cancer Research, 2013
- Development and Validation of a Prognostic Model Using Blood Biomarker Information for Prediction of Survival of Non–Small-Cell Lung Cancer Patients Treated With Combined Chemotherapy and Radiation or Radiotherapy Alone (NCT00181519, NCT00573040, and NCT00572325)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Osteopontin as a marker of weight loss in lung cancerScandinavian Journal of Clinical and Laboratory Investigation, 2011
- Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancerChinese Journal of Cancer Research, 2011
- Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastomaImmunology, 2010
- Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective studyLung Cancer, 2010
- Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancerLung Cancer, 2009